Literature DB >> 20140355

Multidrug-resistant bacteria isolated from intensive-care-unit patient samples.

Aziz Japoni1, Afsaneh Vazin, Mahdi Hamedi, Mohammad Ali Davarpanah, Abdolvahab Alborzi, Noraladin Rafaatpour.   

Abstract

We examined epidemiological aspects and bacterial resistance patterns of bacteria isolated from intensive care unit (ICU) patient samples. During a 10 month period (from June 2006 to March 2007), 812 samples of blood, urine and cerebral spinal fluid (CSF) from 553 hospitalized patients, in ICU wards, including pediatric surgical, neonatal, adult surgical I, adult surgical II, general pediatrics, neurosurgical I, neurosurgical II, and internal medical, were collected. Minimum inhibitory concentration (MIC) of antibiotics for bacteria isolates was determined by the E-test method. The internal medicine ICU with 28.7% admissions gave the largest contribution. Coagulase negative staphylococci at frequencies of 66.7 % and 36.5 % and E. coli at 20.9% were the bacteria most frequently isolated from the blood, CSF and urine samples, respectively. Samples taken from patients 20-40 years old were the most frequent (32.2%), while the group of patients over sixty years contributed least (18.5%). Both Gram-positive and - negative isolates expressed resistance to most of the penicillins and cephalosporins tested. Combined therapy with vancomycin and meropenem or imipenem gave the most effective treatment against Gram-positive and Gram-negative isolates based on empirical therapy. High frequencies of multiresistant bacteria in ICUs warn us to administer a few effective antibiotics in our hospitals more wisely in order to reduce selective pressure on sensitive strains. This could help save the life of ICU patients and prevent of spread of resistant isolates in these critical wards. Due to continuous changes in antibacterial susceptibility patterns, periodical antibacterial sensitivity assessment in ICUs should be mandatory.

Entities:  

Mesh:

Year:  2009        PMID: 20140355     DOI: 10.1590/s1413-86702009000200009

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  Prevalence of Multidrug-Resistant Pathogens Causing Bloodstream Infections in an Intensive Care Unit.

Authors:  Andreea-Loredana Golli; Oana Mariana Cristea; Adina-Dorina Glodeanu; Ovidiu Zlatian; Andrei Theodor Balasoiu; Mihaela Ionescu; Simona Popa
Journal:  Infect Drug Resist       Date:  2022-10-17       Impact factor: 4.177

2.  Case fatality rate related to nosocomial and ventilator-associated pneumonia in an ICU: a single-centre retrospective cohort study.

Authors:  Murat Yalçınsoy; Cuneyt Salturk; Hurıye Berk Takır; Semra Batı Kutlu; Ayşegul Oguz; Emine Aksoy; Merih Balcı; Feyza Kargın; Ozlem Yazıcıoglu Mocin; Nalan Adıguzel; Gokay Gungor; Zuhal Karakurt
Journal:  Wien Klin Wochenschr       Date:  2015-11-05       Impact factor: 1.704

3.  Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran.

Authors:  Masoomeh Bayani; Sepideh Siadati; Ramzan Rajabnia; Ali Asghar Taher
Journal:  Int J Mol Cell Med       Date:  2013

4.  Isolation and Antibiotic Susceptibility of the Microorganisms Isolated from Diabetic Foot Infections in Nemazee Hospital, Southern Iran.

Authors:  Mojtaba Anvarinejad; Gholamreza Pouladfar; Aziz Japoni; Shahram Bolandparvaz; Zeinab Satiary; Pejman Abbasi; Jalal Mardaneh
Journal:  J Pathog       Date:  2015-12-30

5.  Bacteriological Profile of Diabetic Foot Ulcer with Special Reference to Drug-resistant Strains in a Tertiary Care Center in North-East India.

Authors:  Sudhir K Jain; Rashmisnata Barman
Journal:  Indian J Endocrinol Metab       Date:  2017 Sep-Oct

6.  Ecology of blood stream infection and antibiotic resistance in intensive care unit at a tertiary care hospital in North India.

Authors:  Chand Wattal; Reena Raveendran; Neeraj Goel; Jaswinder Kaur Oberoi; Brijendra Kumar Rao
Journal:  Braz J Infect Dis       Date:  2014-01-03       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.